Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.

Journal of medical genetics - 1 Jun 2014

Núñez Concepción, Cénit M Carmen, Alvarez-Lafuente Roberto, Río Jordi, Fernández-Arquero Miguel, Arroyo Rafael, Montalbán Xavier, Fernández Oscar, Oliver-Martos Begoña, Leyva Laura, Comabella Manuel, Urcelay Elena

Abstract excerpt

BACKGROUND: Recombinant interferon β (IFNβ) is a first-line therapy for relapsing-remitting multiple sclerosis (MS), with a proven effect on the inflammatory activity. Neutralising antibodies against IFNβ (NAbs) promote a loss of IFNβ bioactivity in a titre-dependent way and their development was associated with certain human leucocyte antigen (HLA) alleles. We investigated the contribution conferred by HLA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-DQ alpha-Chains

Share to HLA-DRB1 Chains

Share to Interferon-beta

Share to Multiple Sclerosis

Share to Multiple Sclerosis Research Studies

Share to Pharmacogenetics

Source

Identifiers

PMID: 24748646
DOI: 10.1136/jmedgenet-2014-102348

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.PMID 24748646Read ↗

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.Semantic proximity Read ↗

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.Semantic proximity Read ↗

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-betaSemantic proximity Read ↗

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.Semantic proximity Read ↗

Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis.Semantic proximity Read ↗

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.Semantic proximity Read ↗

Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment.Semantic proximity Read ↗

HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.Semantic proximity Read ↗

Identification of new sensitive biomarkers for the <i>in vivo</i> response to interferon‐β treatment in multiple sclerosis using DNA‐array evaluationSemantic proximity Read ↗

Immunopharmacological consequences of immune responses to therapeutic interferon betaSemantic proximity Read ↗

Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.Semantic proximity Read ↗

HLA Genes as Modifiers of Response to IFN-β-1a Therapy in Relapsing-Remitting Multiple SclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.